Who is sponsoring NCT03820726?

NCT03820726 is sponsored by Boehringer Ingelheim.

What condition does NCT03820726 study?

NCT03820726 studies Lung Diseases, Interstitial.

What is the status of NCT03820726?

NCT03820726 is currently COMPLETED.

Last reviewed 2023-09-13 · How we verify

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT03820726 PHASE3 COMPLETED Results posted

The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILD® (trial 1199.247).

Details

Lead sponsor	Boehringer Ingelheim
Phase	PHASE3
Status	COMPLETED
Enrolment	435
Start date	Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Lung Diseases, Interstitial

Interventions

Nintedanib

Countries

France, Italy, Japan, Russia, Belgium, Chile, United Kingdom, Germany, Poland, South Korea, Argentina, Canada, China, United States, Spain